Voro Therapeutics announces research collaboration to advance conditionally activated biologics for immunology and inflammation

SAN DIEGO - September 24, 2026 We're excited to announce that Voro Therapeutics, a JLABS San Diego resident company, has entered into a research collaboration with Johnson & Johnson to advance our PrimeBody™ technology in immunology and inflammation.

The collaboration will evaluate Voro's PrimeBody platform to discover conditionally activated biologics designed to switch on selectively in diseased tissue, with the potential to improve selectivity and therapeutic index and expand the range of targets that can be addressed across immune-mediated diseases.

"We believe PrimeBody has the potential to enable a new generation of biologics that activate selectively where they are needed," said Ugur Eskiocak. "This collaboration provides an opportunity to evaluate that approach in inflammatory bowel disease and explore its broader potential across immune-mediated diseases."

About Voro Therapeutics

Voro Therapeutics is a biotechnology company developing the next generation of engineered precision biologics that deliver potent therapeutic activity only where disease is present. Its PrimeBody™ platform is designed to unlock inaccessible targets by overcoming the systemic toxicity that limits conventional biologics through selective activation within diseased tissue. The company's lead program is a first-in-class conditionally activated CD47 inhibitor that combines high-affinity target engagement with Fc enhancement to overcome the historical safety and exposure limitations of CD47 blockade. The program has demonstrated curative activity in preclinical models and is currently advancing through IND-enabling studies. PrimeBody™ is broadly applicable across T-cell engagers, antibody-drug conjugates (ADCs), cytokines, CD47-targeted therapies, and other modalities, enabling a diversified pipeline across oncology and immune-mediated diseases.